Browse News
Filter News
Found 5 articles
-
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/30/2023
Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
-
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
-
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/15/2022
Icosavax, Inc. (Nasdaq: ICVX), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Icosavax, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
9/13/2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.